PD-L1/BCMA targeting bispecific antibody (Immune Pharmaceuticals)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NamePD-L1/BCMA targeting bispecific antibody (Immune Pharmaceuticals)

Drug Alias NamePD-L1 checkpoint inhibitor (Immune Pharmaceuticals)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionProgrammed death-ligand 1 blockersTumor necrosis factor ligand superfamily member 13 modulators

TargetsTumor necrosis factor ligand superfamily member 13Programmed death-ligand 1

Therapy Area/IndicationsMultiple Myeloma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryIsrael

CombinationsNo

Global Highest StatusSuspended

Highest Status in ChinaN/A

Originator CompaniesImmune Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesImmune Pharmaceuticals Inc

Inactive CompaniesN/A

Active IndicationsMultiple Myeloma

Inactive IndicationsN/A

Other Information

ATC CodeN/A